Long-term follow-up of immunosuppressive monotherapy in liver transplantation: Tacrolimus and microemulsified cyclosporin

Clinical Transplantation

Volumn 25, Issue 4, 2011, Pages 614-624

  Cholongitas, Evangelos ^a,b   Shusang, Vibhakorn ^a   Germani, Giacomo ^a   Tsochatzis, Emmanuel ^a   Raimondo, Maria Luisa ^a   Marelli, Laura ^a   Senzolo, Marco ^a   Davidson, Brian R ^a   Patch, David ^a   Rolles, Keith ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Aristotle University of Thessaloniki   (Greece)

Author keywords

Cyclosporin; Immunosuppression; Liver transplantation; Monotherapy; Tacrolimus

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MONOTHERAPY; PRIORITY JOURNAL; RETRANSPLANTATION; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; CYCLOSPORINE; EMULSIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SURVIVAL RATE; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955058932     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01321.x     Document Type: Article

References (33)

1. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989: 2: 1000.
2. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006:CD005161.
3. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006: 6: 1578.
4. O'Grady JG, Hardy P, Burroughs AK, Elbourne D. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3years. Am J Transplant 2007: 7: 137.
5. Junge G, Neuhaus R, Schewior L et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc 2005: 37: 1695.
6. Fraser GM, Grammoustianos K, Reddy J, Rolles K, Davidson B, Burroughs AK. Long-term immunosuppression without corticosteroids after orthotopic liver transplantation: a positive therapeutic aim. Liver Transpl Surg 1996: 2: 411.
7. Otto G, Bleyl J, Neuhaus P et al. Corticosteroids and concomitant medication in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. Transpl Int 1994: 7(Suppl. 1): S7.
8. Calne RY, White DJ, Thiru S et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978: 2: 1323.
9. Calne RY, Rolles K, White DJ et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979: 2: 1033.
10. Romani F, Belli LS, De CL et al. Cyclosporin monotherapy (after 3months) in liver transplant patients: a prospective randomized trial. Transplant Proc 1994: 26: 2683.
11. Matl I, Lacha J, Lodererova A et al. Withdrawal of steroids from triple-drug therapy in kidney transplant patients. Nephrol Dial Transplant 2000: 15: 1041.
12. Segev DL, Sozio SM, Shin EJ et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008: 14: 512.
13. Trail KC, McCashland TM, Larsen JL et al. Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation. Liver Transpl Surg 1996: 2: 276.
14. Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 1995: 60: 1057.
15. Rolles K, Davidson BR, Burroughs AK. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. Transplantation 1999: 68: 1195.
16. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002: 360: 1119.
17. Datta GS, Hudson M, Burroughs AK et al. Grading of cellular rejection after orthotopic liver transplantation. Hepatology 1995: 21: 46.
18. Demetris AJ, Adeyi O, Bellamy CO et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006: 44: 489.
19. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis 2009: 53: S4.
20. Cholongitas E, Shusang V, Marelli L et al. Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther 2007: 26: 969.
21. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004: 10: 301.
22. Abbasoglou O. Liver transplantation: yesterday, today and tomorrow. World J Gastroenterol 2008: 14: 3117.
23. Jorga A, Johnston A. Novel therapies in transplantation. Expert Opin Investig Drugs 2005: 14: 295.
24. Tippner C, Nashan B, Hoshino K et al. Clinical and subclinical acute rejection early after liver transplantation: contributing factors and relevance for the long-term course. Transplantation 2001: 72: 1122.
25. Wiesner RH, Demetris AJ, Belle SH et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998: 28: 638.
26. Gonzalez-Pinto IM, Rimola A, Margarit C et al. Five-year follow-up of a trial comparing Tacrolimus and cyclosporine microemulsion in liver transplantation. Transplant Proc 2005: 37: 1713.
27. Jain A, Marcos A, Reyes J et al. Tacrolimus for primary liver transplantation: 12 to 15years actual follow-up with safety profile. Transplant Proc 2005: 37: 1207.
28. Sheiner P, Magliocca J, Bodian C. Long-term medical complications in patients surviving > or = 5years after liver transplant. Transplantation 2000: 69: 781.
29. Burroughs AK, Sabin CA, Rolles K et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 2006: 367: 225.
30. Margarit C, Bilbao I, Castells L et al. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 2005: 18: 1336.
31. Lerut J, Mathys J, Verbaandert C et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. Ann Surg 2008: 248: 956.
32. Raimondo ML, Burroughs AK. Single-agent immunosuppression after liver transplantation: what is possible? Drugs 2002: 62: 1587.
33. Manousou P, Samonakis D, Cholongitas E et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009: 15: 1783.